Cited by 703Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

Open access

Perrin, Richard J., Fagan, Anne M., Holtzman, David M.·2009·Nature

DOI 10.1038/nature08538PMC PMC2810658

Open this paper in CoChat — free account

Abstract

Alzheimer's disease affects millions of people around the world. Currently, there are no treatments that prevent or slow the disease. Like other neurodegenerative diseases, Alzheimer's disease is characterized by protein misfolding in the brain. This process and the associated brain damage begin years before the substantial neurodegeneration that accompanies dementia. Studies using new neuroimaging techniques and fluid biomarkers suggest that Alzheimer's disease pathology can be detected preclinically. These advances should allow the design of new clinical trials and early mechanism-based therapeutic intervention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature08538

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Brain's Default Network: Anatomy, Function, and Relevance to Disease
Buckner, R. L., Andrews‐Hanna, J. R., & Schacter, D. L. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1440.011 · Cited by 9,761
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Searching for a baseline: Functional imaging and the resting human brain
Gusnard, D. A., & Raichle, M. E. (2001) · Nature Reviews Neuroscience · doi:10.1038/35094500 · Cited by 3,371
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499

Flagged first, then by citations

Show all 83 references

Research works printed but not linked: 3

Alzheimer, A. About a peculiar disease of the cerebral cortex [translation]. Alzheimer Dis. Assoc. Disord. 1, 7–8 (1987).
Morris J. C. et al. PIB imaging predicts progression to symptomatic Alzheimer's disease. Arch. Neurol. (in the press).
Cairns, N. J. et al. PiB-PET detection of cerebral Aβ may lag clinical, cognitive, and CSF markers of Alzheimer's disease: a case report. Arch. Neurol. (in the press).

Sorted by citations

Items 101–200 of 703

Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3405 · Cited by 145
Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42
Schott, J. M., Bartlett, J. W., Fox, N. C., Barnes, J., & Initiative, A. D. N. (2010) · Annals of Neurology · doi:10.1002/ana.22315 · Cited by 146
Detecting tissue-specific early warning signals for complex diseases based on dynamical network biomarkers: study of type 2 diabetes by cross-tissue analysis
Li, M., Zeng, T., Liu, R., & Chen, L. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbt027 · Cited by 142
Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early alzheimer's disease
Chiu, M., Chen, Y., Chen, T., Yang, S., Yang, F., Tseng, T.-W., Chieh, J.-J., Chen, J.-C. R., Tzen, K., Hua, M., et al. (2013) · Human Brain Mapping · doi:10.1002/hbm.22390 · Cited by 144
A novel role for osteopontin in macrophage-mediated amyloid-β clearance in Alzheimer’s models
Rentsendorj, A., Sheyn, J., Fuchs, D.-T. S., Daley, D. A., Salumbides, B. C., Schubloom, H. E., Hart, N. J., Li, S., Hayden, E. Y., Teplow, D. B., et al. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.08.019 · Cited by 143
Twenty years of Alzheimer’s disease‐causing mutations
Goate, A., & Hardy, J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07575.x · Cited by 141
Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease
Galvin, J. E., Price, J. L., Yan, Z., Morris, J. C., & Sheline, Y. I. (2011) · Neurology · doi:10.1212/wnl.0b013e31821ccc83 · Cited by 137
Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
Björkqvist, M., Ohlsson, M., Minthon, L., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029868 · Cited by 135
Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years
Hertze, J., Minthon, L., Zetterberg, H., Vanmechelen, E., Blennow, K., & Hansson, O. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100207 · Cited by 135
Inflammasomes as therapeutic targets for A lzheimer's disease
White, C., Lawrence, C. B., Brough, D., & Rivers‐Auty, J. (2016) · Brain Pathology · doi:10.1111/bpa.12478 · Cited by 136
Cerebral amyloid PET imaging in Alzheimer’s disease
Jack, C. R., Barrio, J. R., & Kepe, V. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1185-7 · Cited by 137
Alzheimer’s Retinopathy: Seeing Disease in the Eyes
Mirzaei, N., Shi, H., Oviatt, M., Doustar, J., Rentsendorj, A., Fuchs, D.-T. S., Sheyn, J., Black, K. L., Koronyo, Y., & Koronyo‐Hamaoui, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00921 · Cited by 136
The role of egocentric and allocentric abilities in Alzheimer's disease: A systematic review
Serino, S., Cipresso, P., Morganti, F., & Riva, G. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.04.004 · Cited by 136
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Increased plasma beta-secretase 1 may predict conversion to Alzheimer’s disease dementia in individuals with mild cognitive impairment
Shen, Y., Wang, H., Sun, Q., Yao, H., Keegan, A. P., Mullan, M., Wilson, J., Lista, S., Leyhe, T., Laske, C., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.02.007 · Cited by 123
Cerebrospinal Fluid Biomarkers of Neurovascular Dysfunction in Mild Dementia and Alzheimer'S Disease
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.76 · Cited by 122
Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment
Pinho, B. R., Ferreres, F., Valentão, P., & Andrade, P. B. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12081 · Cited by 118
Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis
Dhiman, K., Blennow, K., Zetterberg, H., Martins, R. N., & Gupta, V. B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03040-5 · Cited by 117
The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics
Bos, I., Vos, S., Vandenberghe, R., Scheltens, P., Engelborghs, S., Frisoni, G., Molinuevo, J. L., Wallin, A., Lleó, A., Popp, J., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0396-5 · Cited by 112
SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy
Winer, L. K., Srinivasan, D., Chun, S. J., Lacomis, D., Jaffa, M., Fagan, A. M., Holtzman, D. M., Wancewicz, E. V., Bennett, C. F., Bowser, R. P., et al. (2012) · JAMA Neurology · doi:10.1001/jamaneurol.2013.593 · Cited by 113
Self-citation
Two Distinct Amyloid β-Protein (Aβ) Assembly Pathways Leading to Oligomers and Fibrils Identified by Combined Fluorescence Correlation Spectroscopy, Morphology, and Toxicity Analyses
Matsumura, S., Shinoda, K., Yamada, M., Yokojima, S., Inoue, M., Ohnishi, T., Shimada, T., Kikuchi, K., Masui, D., Hashimoto, S., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.181313 · Cited by 115
Tau binding protein CAPON induces tau aggregation and neurodegeneration
Hashimoto, S., Matsuba, Y., Kamano, N., Mihira, N., Sahara, N., Takano, J., Muramatsu, S.-I., Saido, T. C., & Saito, T. (2019) · Nature Communications · doi:10.1038/s41467-019-10278-x · Cited by 111
Apolipoprotein E4 Causes Age- and Sex-Dependent Impairments of Hilar GABAergic Interneurons and Learning and Memory Deficits in Mice
Leung, L., Andrews-Zwilling, Y., Yoon, S. Y., Jain, S., Ring, K., Dai, J., Wang, M. M., Tong, L., Walker, D., & Huang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053569 · Cited by 109
Detection of the tau protein in human serum by a sensitive four-electrode electrochemical biosensor
Wang, S. X., Acha, D., Shah, A. J., Hills, F. A., Roitt, I. M., Demosthenous, A., & Bayford, R. H. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.10.077 · Cited by 109
Genetics of Alzheimer disease in the pre- and post-GWAS era
Ertekin‐Taner, N. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt26 · Cited by 112
Aromatic-turmerone induces neural stem cell proliferation in vitro and in vivo
Hucklenbroich, J., Klein, R. M., Neumaier, B., Graf, R., Fink, G. R., Schroeter, M., & Rueger, M. A. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt500 · Cited by 106
A practical Alzheimer’s disease classifier via brain imaging-based deep learning on 85,721 samples
Lu, B., Li, H., Chang, Z., Li, L., Chen, N.-X., Zhu, Z.-C., Zhou, H., Li, X., Wang, Y., Cui, S., et al. (2022) · Journal Of Big Data · doi:10.1186/s40537-022-00650-y · Cited by 106
Increased fragmentation of sleep–wake cycles in the 5XFAD mouse model of Alzheimer’s disease
Sethi, M., Joshi, S., Webb, R. L., Beckett, T. L., Donohue, K. D., Murphy, M. P., O’Hara, B. F., & Duncan, M. J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.035 · Cited by 109
Incomplete multi-modal representation learning for Alzheimer’s disease diagnosis
Liu, Y., Fan, L., Zhang, C., Zhou, T., Xiao, Z., Geng, L., & Shen, D. (2021) · Medical Image Analysis · doi:10.1016/j.media.2020.101953 · Cited by 102
miR‐186 is decreased in aged brain and suppresses BACE 1 expression
Kim, J., Yoon, H., Chung, D., Brown, J. L., Belmonte, K. C., & Kim, J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13507 · Cited by 102
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., Salter, H., Potter, W. Z., Sperling, R. A., Bateman, R. J., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.001 · Cited by 102
A CNN–RNN–LSTM Based Amalgamation for Alzheimer’s Disease Detection
Dua, M., Makhija, D., Manasa, P., & Mishra, P. (2020) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-020-00556-1 · Cited by 102
Alzheimer's disease pathophysiology in the Retina
Gaire, B. P., Koronyo, Y., Fuchs, D.-T. S., Shi, H., Rentsendorj, A., Danziger, R., Vit, J., Mirzaei, N., Doustar, J., Sheyn, J., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101273 · Cited by 107
Relationship of dementia screening tests with biomarkers of Alzheimer's disease
Galvin, J. E., Fagan, A. M., Holtzman, D. M., Mintun, M. A., & Morris, J. C. (2010) · Brain · doi:10.1093/brain/awq204 · Cited by 103
Self-citation
Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer’s disease
Sang, Z., Wang, K., Shi, J., Cheng, X., Zhu, G., Wei, R., Ma, Q., Yu, L., Zhao, Y., Tan, Z., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111958 · Cited by 102
Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy
Yanamandra, K., Patel, T. K., Jiang, H., Schindler, S., Ulrich, J. D., Boxer, A. L., Miller, B. L., Kerwin, D. R., Gallardo, G., Stewart, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2029 · Cited by 100
Self-citation
Amphiphilic Distyrylbenzene Derivatives as Potential Therapeutic and Imaging Agents for Soluble and Insoluble Amyloid β Aggregates in Alzheimer’s Disease
Sun, L., Cho, H.-J., Sen, S., Arango, A. S., Huynh, T. T., Huang, Y., Bandara, N., Rogers, B. E., Tajkhorshid, E., & Mirica, L. M. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c05470 · Cited by 101
Preparation of near-infrared AIEgen-active fluorescent probes for mapping amyloid-β plaques in brain tissues and living mice
Yan, C., Dai, J., Yao, Y., Fu, W., Tian, H., Zhu, W., & Guo, Z. (2023) · Nature Protocols · doi:10.1038/s41596-022-00789-1 · Cited by 100
The presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ deposition in the brain
Hamaguchi, T., Eisele, Y. S., Varvel, N. H., Lamb, B. T., Walker, L. C., & Jucker, M. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0912-1 · Cited by 105
Glutamate receptors in preclinical research on Alzheimer's disease: Update on recent advances
Hu, N., Ondrejčák, T., & Rowan, M. J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.013 · Cited by 99
Heat Shock Protein Inspired Nanochaperones Restore Amyloid-β Homeostasis for Preventative Therapy of Alzheimer’s Disease
Yang, H., Li, X., Zhu, L., Wu, X., Zhang, S., Huang, F., Feng, X., & Shi, L. (2019) · Advanced Science · doi:10.1002/advs.201901844 · Cited by 98
Canonical feature selection for joint regression and multi-class identification in Alzheimer’s disease diagnosis
Zhu, X., Suk, H., Lee, S., & Shen, D. G. (2015) · Brain Imaging and Behavior · doi:10.1007/s11682-015-9430-4 · Cited by 97
Integrated magnetic resonance imaging and [11C]‐PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis
Alshikho, M. J., Zürcher, N. R., Loggia, M. L., Cernasov, P., Reynolds, B., Pijanowski, O., Chonde, D. B., Izquierdo‐Garcia, D., Mainero, C., Catana, C., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25251 · Cited by 99
Mass Spectrometry Imaging, an Emerging Technology in Neuropsychopharmacology
Shariatgorji, M., Svenningsson, P., & Andrén, P. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.215 · Cited by 99
Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice
Knoferle, J., Yoon, S. Y., Walker, D., Leung, L., Gillespie, A. K., Tong, L. M., Bien-Ly, N., & Huang, Y. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.2281-14.2014 · Cited by 97
Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review
Benedict, C., & Grillo, C. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00215 · Cited by 101
Aging-related cortical reorganization of verbal fluency processing: a functional near-infrared spectroscopy study
Heinzel, S., Metzger, F. G., Ehlis, A., Korell, R., Alboji, A., Haeussinger, F. B., Hagen, K., Maetzler, W., Eschweiler, G. W., Berg, D., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.05.021 · Cited by 100
Brain aerobic glycolysis functions and Alzheimer’s disease
Vlassenko, A. G., & Raichle, M. E. (2014) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0094-7 · Cited by 96
Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease
Echeverría, V., Iarkov, A., & Aliev, G. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.002 · Cited by 95
Principles and challenges of modeling temporal and spatial omics data
Velten, B., & Stegle, O. (2023) · Nature Methods · doi:10.1038/s41592-023-01992-y · Cited by 96
Postoperative cognitive dysfunction, Alzheimer's disease, and anesthesia
Arora, S. S., Gooch, J. L., & García, P. S. (2013) · International Journal of Neuroscience · doi:10.3109/00207454.2013.833919 · Cited by 90
The tension between early diagnosis and misdiagnosis of multiple sclerosis
Solomon, A. J., & Corboy, J. R. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.106 · Cited by 89
Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights
Villa, C., Lavitrano, M., Salvatore, E., & Combi, R. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030061 · Cited by 94
In vivo detection of amyloid β deposition using 19F magnetic resonance imaging with a 19F-containing curcumin derivative in a mouse model of Alzheimer's disease
Yanagisawa, D., Amatsubo, T., Morikawa, S., Taguchi, H., Urushitani, M., Shirai, N., Hirao, K., Shiino, A., Inubushi, T., & Tooyama, I. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.03.071 · Cited by 89
Region and frequency specific changes of spectral power in Alzheimer’s disease and mild cognitive impairment
Roh, J. H., Park, M. H., Ko, D., Park, K. W., Lee, D.-H., Han, C., Jo, S. A., Yang, K., & Jung, K. (2011) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.03.023 · Cited by 87
Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
Fagan, A. M., & Holtzman, D. M. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.83 · Cited by 88
Self-citation
A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics
Song, L., Lachno, D. R., Hanlon, D., Shepro, A., Jeromin, A., Gemani, D., Talbot, J. A., Racke, M. M., Dage, J. L., & Dean, R. A. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0225-7 · Cited by 86
How random is the random forest? Random forest algorithm on the service of structural imaging biomarkers for Alzheimer's disease: from Alzheimer's disease neuroimaging initiative (ADNI) database
Dimitriadis, S. I., Liparas, D., & Alzheimer's, D. N. I. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.233433 · Cited by 85
Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI
Holland, D., McEvoy, L. K., Dale, A. M., & Initiative, T. A. D. N. (2011) · Human Brain Mapping · doi:10.1002/hbm.21386 · Cited by 85
ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker
Manzine, P. R., Ettcheto, M., Cano, A. C., Busquets, O., Marcello, E. E., Pelucchi, S., Luca, M. D., Endres, K., Olloquequi, J., Camins, A., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108661 · Cited by 84
Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice
Trueba-Sáiz, Á., Cavada, C., Fernandez, A. M., Leon, T., González, D. A., Fortea, J., Lleó, A., del Ser, T., Núñez, Á., & Torres‐Alemán, I. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.102 · Cited by 86
Origins of Alzheimerʼs disease
Musiek, E. S., & Holtzman, D. M. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835a30f4 · Cited by 85
Self-citation
Impacts of Methylxanthines and Adenosine Receptors on Neurodegeneration: Human and Experimental Studies
Chen, J., & Chern, Y. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-13443-2_10 · Cited by 85
Impaired Lipoprotein Receptor-Mediated Peripheral Binding of Plasma Amyloid-β is an Early Biomarker for Mild Cognitive Impairment Preceding Alzheimer's Disease
Sagare, A. P., Deane, R., Zetterberg, H., Wallin, A., Blennow, K., & Zloković, B. V. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101248 · Cited by 83
Interneurons, tau and amyloid-β in the piriform cortex in Alzheimer’s disease
Saiz-Sanchez, D., De la Rosa-Prieto, C., Ubeda-Banon, I., & Martinez-Marcos, A. (2015) · Brain Structure and Function · doi:10.1007/s00429-014-0771-3 · Cited by 79
Alzheimer Disease Pathology in Subjects Without Dementia in 2 Studies of Aging: The Nun Study and the Adult Changes in Thought Study
SantaCruz, K. S., Sonnen, J. A., Pezhouh, M. K., Desrosiers, M. F., Nelson, P. T., & Tyas, S. L. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31822e8ae9 · Cited by 79
Midlife cardiovascular risk factors and late cognitive impairment
Virta, J. J., Heikkila, K. V., Perola, M., Koskenvuo, M. J., Räihä, I. J., Rinne, J. O., & Kaprio, J. A. (2013) · European Journal of Epidemiology · doi:10.1007/s10654-013-9794-y · Cited by 83
Development of a high-sensitivity immunoassay for amyloid-beta 1–42 using a silicon microarray platform
Gagni, P., Solá, L., Cretich, M., & Chiari, M. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.03.077 · Cited by 78
Mapping the Road Forward in Alzheimer’s Disease
Holtzman, D. M., Goate, A., Kelly, J. W., & Sperling, R. A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003529 · Cited by 81
Self-citation
Cross-talk of membrane lipids and Alzheimer-related proteins
Walter, J., & van Echten‐Deckert, G. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-34 · Cited by 79
Lycopene mitigates β-amyloid induced inflammatory response and inhibits NF-κB signaling at the choroid plexus in early stages of Alzheimer’s disease rats
Liu, C., Wang, R., Yi, Y., Gao, Z., & Chen, Y. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.10.014 · Cited by 81
Evaluation of 64Cu-Based Radiopharmaceuticals that Target Aβ Peptide Aggregates as Diagnostic Tools for Alzheimer’s Disease
Bandara, N., Sharma, A. K., Krieger, S., Schultz, J. W., Han, B. H., Rogers, B. E., & Mirica, L. M. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b05937 · Cited by 82
Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice
Huang, H., Nie, S., Cao, M., Marshall, C., Gao, J., Xiao, N., Hu, G., & Xiao, M. (2016) · AGE · doi:10.1007/s11357-016-9929-7 · Cited by 79
Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
Insel, P. S., Ossenkoppele, R., Gessert, D., Jagust, W., Landau, S. M., Hansson, O., Weiner, M. W., & Mattsson, N. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00281 · Cited by 75
Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
Balducci, C., & Forloni, G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00738 · Cited by 74
In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer’s Disease
More, S. S., Beach, J. M., McClelland, C. M., Mokhtarzadeh, A., & Vince, R. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00331 · Cited by 74
Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes
Piccialli, I., Tedeschi, V., Caputo, L., D’Errico, S., Ciccone, R., De Feo, V., Secondo, A., & Pannaccione, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876614 · Cited by 73
A Review of Oxidative Stress Products and Related Genes in Early Alzheimer’s Disease
Cioffi, F., Adam, R. H. I., Bansal, R., & Broersen, K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210497 · Cited by 73
An attention-based deep learning approach for the classification of subjective cognitive decline and mild cognitive impairment using resting-state EEG
Sibilano, E., Brunetti, A., Buongiorno, D., Lassi, M., Grippo, A., Bessi, V., Micera, S., Mazzoni, A., & Bevilacqua, V. (2023) · Journal of Neural Engineering · doi:10.1088/1741-2552/acb96e · Cited by 74
Peripheral Blood Mononuclear Cells as a Laboratory to Study Dementia in the Elderly
Arosio, B., D’Addario, C., Gussago, C., Casati, M., Tedone, E., Ferri, E., Nicolini, P., Rossi, P. D., Maccarrone, M., & Mari, D. (2014) · BioMed Research International · doi:10.1155/2014/169203 · Cited by 73
Omega-3 polyunsaturated fatty acids promote brain-to-blood clearance of β-Amyloid in a mouse model with Alzheimer’s disease
Yan, L., Xie, Y., Satyanarayanan, S. K., Zeng, H., Liu, Q., Huang, M., Ma, Y., Wan, J., Yao, X., Su, K., et al. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.05.033 · Cited by 75
Environmental neuroscience linking exposome to brain structure and function underlying cognition and behavior
Liu, F., Xu, J., Guo, L., Qin, W., Liang, M., Schumann, G., & Yu, C. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01669-6 · Cited by 72
Discriminative Learning for Alzheimer's Disease Diagnosis via Canonical Correlation Analysis and Multimodal Fusion
Lei, B., Chen, S., Ni, D., & Wang, T. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00077 · Cited by 72
Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targeting
Plissonneau, M., Pansieri, J., Heinrich, L., Morfin, J., Stransky-Heilkron, N., Rivory, P., Mowat, P., Dumoulin, M., Cohen, R., Allémann, É., et al. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0212-y · Cited by 74
Modeling of Pathological Traits in Alzheimer's Disease Based on Systemic Extracellular Signaling Proteome
Britschgi, M., Rufibach, K., Huang, S. L. B., Clark, C. M., Kaye, J. A., Li, G., Peskind, E. R., Quinn, J. F., Galasko, D. R., & Wyss‐Coray, T. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.008862 · Cited by 73
Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer’s disease
Yan, R., Fan, Q., Zhou, J., & Vassar, R. J. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.025 · Cited by 71
Imaging mass spectrometry (IMS) of cortical lipids from preclinical to severe stages of Alzheimer's disease
Román, E. G. D. S., Manuel, I., Giralt, M. T., Ferrer, I., & Rodríguez‐Puertas, R. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.05.009 · Cited by 71
Leveraging Coupled Interaction for Multimodal Alzheimer’s Disease Diagnosis
Shi, Y., Suk, H., Gao, Y., Lee, S., & Shen, D. G. (2019) · IEEE Transactions on Neural Networks and Learning Systems · doi:10.1109/tnnls.2019.2900077 · Cited by 71
Resting-state global brain activity affects early β-amyloid accumulation in default mode network
Han, F., Liu, X., Mailman, R. B., Huang, X., Liu, X., & Initiative, T. A. D. N. (2023) · Nature Communications · doi:10.1038/s41467-023-43627-y · Cited by 68
Accurate Prediction of Conversion to Alzheimer’s Disease using Imaging, Genetic, and Neuropsychological Biomarkers
Dukart, J., Sambataro, F., Bertolino, A., & Initiative, A. D. N. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150570 · Cited by 68
“Amyloid‐beta accumulation cycle” as a prevention and/or therapy target for Alzheimer's disease
Rao, C. V., Asch, A. S., Carr, D. J. J., & Yamada, H. Y. (2020) · Aging Cell · doi:10.1111/acel.13109 · Cited by 69
Explainable Artificial Intelligence of Multi-Level Stacking Ensemble for Detection of Alzheimer’s Disease Based on Particle Swarm Optimization and the Sub-Scores of Cognitive Biomarkers
AlMohimeed, A., Saad, R. M. A., Mostafa, S., El-Rashidy, N. M., Farrag, S., Gaballah, A., Elaziz, M. A., El–Sappagh, S., & Saleh, H. (2023) · IEEE Access · doi:10.1109/access.2023.3328331 · Cited by 67
Getting lost in Alzheimer’s disease: A break in the mental frame syncing
Serino, S., & Riva, G. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2012.12.031 · Cited by 74
Nanotheranostics, a future remedy of neurological disorders
Sharma, M., Dube, T., Chibh, S., Kour, A., Mishra, J., & Panda, J. J. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1562443 · Cited by 67
A gene expression phenotype in lymphocytes from friedreich ataxia patients
Coppola, G., Burnett, R., Perlman, S., Versano, R., Gao, F., Plasterer, H. L., Rai, M., Saccà, F., Filla, A., Lynch, D. R., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22526 · Cited by 67
Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis
Rossi, S., Mancino, R., Bergami, A., Mori, F., Castelli, M., Chiara, V. D., Studer, V., Mataluni, G., Sancesario, G. M., Parisi, V., et al. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511410342 · Cited by 66
Amyloid β-Targeted Metal Complexes for Potential Applications in Alzheimer's Disease
Liu, H., Qu, Y., & Wang, X. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0248 · Cited by 70
Fully automated discrimination of Alzheimer’s disease using resting-state electroencephalography signals
Ding, Y., Chu, Y., Liu, M., Ling, Z., Wang, S., Li, X., & Li, Y. (2021) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-21-430 · Cited by 65
Amyloid and Alzheimer's Disease: Inside and Out
Tam, J. H. K., & Pasternak, S. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013408 · Cited by 64
Hierarchical Feature Extraction for Early Alzheimer’s Disease Diagnosis
Yue, L., Gong, X., Li, J., Ji, H., Li, M., & Nandi, A. K. (2019) · IEEE Access · doi:10.1109/access.2019.2926288 · Cited by 63

Authors: Perrin, R. J., Fagan, A. M., & Holtzman, D. M.
Affiliations: Washington University in St. Louis (US)
ORCID: Perrin, Richard J.
Fagan, Anne M.
Holtzman, David M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2009-10
Volume: 461
Issue: 7266
Pages: 916-922
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature08538
PMC: PMC2810658
OpenAlex: W2085558649
Cited by: 702
References: 83
Citations by year: 2026: 20 · 2025: 29 · 2024: 30 · 2023: 28 · 2022: 43 · 2021: 56 · 2020: 38 · 2019: 38 · 2018: 36 · 2017: 48 · 2016: 33 · 2015: 49 · 2014: 53 · 2013: 58 · 2012: 60
FWCI: 5.97
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: National Institutes of Health (5t32ns007205-32)
National Institute on Aging (P50AG005681, P01 AG0 3991, P01AG003991, P50AG00568125, P01AG026276)
National Institute of Neurological Disorders and Stroke (T32-NS007205)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords: Alzheimer's disease, multimodal diagnosis, prognosis, neuroimaging, fluid biomarkers, preclinical detection, protein misfolding, neurodegeneration, dementia, clinical trials
MeSH terms: Alzheimer Disease, Humans, Inflammation, Prognosis, Amyloid beta-Peptides, tau Proteins, Oxidative Stress, Proteomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks